181 related articles for article (PubMed ID: 32191317)
1. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.
Gulhati P; Yin J; Pederson L; Schmoll HJ; Hoff P; Douillard JY; Hecht JR; Tournigand C; Tebbut N; Chibaudel B; Gramont A; Shi Q; Overman MJ
J Natl Cancer Inst; 2020 Nov; 112(11):1127-1136. PubMed ID: 32191317
[TBL] [Abstract][Full Text] [Related]
2. CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Kang S; Kim SY; Hong YS; Kim TW; Choi KE; Kim MJ; Kim JE
Sci Rep; 2023 Apr; 13(1):6735. PubMed ID: 37185297
[TBL] [Abstract][Full Text] [Related]
3. Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
Acta Oncol; 2018 Jun; 57(6):750-758. PubMed ID: 29388498
[TBL] [Abstract][Full Text] [Related]
4. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Moretto R; Rossini D; Conca V; Lonardi S; Rasola C; Antoniotti C; Santini D; Marmorino F; Tomasello G; Borelli B; Caponnetto S; Zucchelli G; Zaniboni A; Ambrosini M; Buonadonna A; Fanchini L; Cupini S; Masi G; Falcone A; Cremolini C
Br J Cancer; 2021 Sep; 125(6):839-845. PubMed ID: 34253871
[TBL] [Abstract][Full Text] [Related]
5. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.
Iwanicki-Caron I; Di Fiore F; Roque I; Astruc E; Stetiu M; Duclos A; Tougeron D; Saillard S; Thureau S; Benichou J; Paillot B; Basuyau JP; Michel P
J Clin Oncol; 2008 Aug; 26(22):3681-6. PubMed ID: 18669452
[TBL] [Abstract][Full Text] [Related]
8. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.
Michl M; Koch J; Laubender RP; Modest DP; Giessen C; Schulz Ch; Heinemann V
Tumour Biol; 2014 Oct; 35(10):10121-7. PubMed ID: 25023402
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
[TBL] [Abstract][Full Text] [Related]
12. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
[TBL] [Abstract][Full Text] [Related]
13. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
Strimpakos AS; Cunningham D; Mikropoulos C; Petkar I; Barbachano Y; Chau I
Ann Oncol; 2010 May; 21(5):1013-9. PubMed ID: 19861580
[TBL] [Abstract][Full Text] [Related]
14. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
Kim G; Jung EJ; Ryu CG; Hwang DY
Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807
[TBL] [Abstract][Full Text] [Related]
16. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
Sefrioui D; Beaussire L; Gillibert A; Blanchard F; Toure E; Bazille C; Perdrix A; Ziegler F; Gangloff A; Hassine M; Elie C; Bignon AL; Parzy A; Gomez P; Thill C; Clatot F; Sabourin JC; Frebourg T; Benichou J; Bouhier-Leporrier K; Gallais MP; Sarafan-Vasseur N; Michel P; Di Fiore F
Br J Cancer; 2021 Aug; 125(5):725-733. PubMed ID: 34112948
[TBL] [Abstract][Full Text] [Related]
18. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of predictive markers for patients with advanced colorectal cancer.
Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
[TBL] [Abstract][Full Text] [Related]
20. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
